TL;DR
This study demonstrates that pre-treating natural killer (NK) cells with interleukin-15 (IL-15) significantly enhances their ability to kill HIV-infected cells when prompted by vaccine-induced antibodies. This optimization of an in vitro assay is crucial for accurately measuring antibody-dependent cellular cytotoxicity (ADCC) responses in HIV vaccine trials, potentially improving the identification of correlates of protection.
What Problem Does This Paper Address?
The RV144 HIV-1 vaccine trial suggested that antibody-dependent cellular cytotoxicity (ADCC) plays a role in protection against HIV infection. ADCC is an immune mechanism where antibodies flag infected cells for destruction by cytotoxic immune cells, primarily Natural Killer (NK) cells. However, in vitro assays designed to measure ADCC in HIV vaccine recipients often struggle to detect these responses effectively, especially compared to responses seen in naturally infected individuals. This difficulty in reliably measuring ADCC responses hinders the identification of crucial immune correlates that could guide the development of more effective HIV vaccines. The researchers hypothesize that the in vivo environment, with its local cytokine milieu, primes NK cells for better ADCC function, and that current in vitro assays using resting NK cells might not fully capture this potential.
Methods
The study employed a modified version of the HIV-1 infectious molecular clone (IMC)-infected target cell assay, also known as the "Luc assay," to measure ADCC. The core innovation was the pre-treatment of NK effector cells with recombinant human IL-15 overnight before co-culture with target cells and plasma samples. This IL-15 treatment aimed to mimic the in vivo activation state of NK cells.
Key methodological aspects included:
- Immunophenotyping: Flow cytometry was used to analyze NK cell subsets, activation markers (like HLA-DR and CD69), and intracellular cytotoxic molecules (perforin and granzyme B) in both untreated and IL-15-treated NK cells.
- Plasma Sample Analysis: Plasma from participants of the HVTN 100 HIV vaccine trial (both vaccine recipients and placebo) was used to assess ADCC activity.
- Optimized Dilution Series and Baseline Subtraction: The study explored a 4-fold dilution series for plasma samples and implemented a baseline subtraction method to account for non-specific killing, aiming to improve the signal-to-noise ratio and better distinguish vaccine-induced responses from background.
- Control Assays: Well-characterized ADCC-mediating monoclonal antibodies (mAbs) specific for HIV-1 or respiratory syncytial virus (Synagis) were used as positive and negative controls, respectively.
Datasets
The study utilized plasma samples from 40 blinded participants of the HVTN 100 phase 1/2 trial. This subset included 34 vaccine recipients and 6 placebo recipients. Samples were collected at baseline and two weeks after the fourth vaccination (month 6.5). Additionally, peripheral blood mononuclear cells (PBMCs) from 15 healthy adult human donors were used for immunophenotyping experiments.
Key Insights and Ideas
- IL-15 as an ADCC Enhancer: The central finding is that IL-15 pretreatment of NK cells significantly boosts their capacity to mediate ADCC in response to vaccine-induced antibodies. This suggests that resting NK cells used in standard assays are not fully representative of their in vivo effector potential.
- Mimicking the In Vivo Environment: IL-15 is a cytokine known to be elevated during acute HIV infection. Using IL-15 in vitro appears to better mimic the activated state of NK cells found at sites of infection, leading to improved ADCC detection.
- Mechanistic Basis for Enhancement: IL-15 treatment leads to increased intracellular levels of perforin and granzyme B in NK cells, which are key molecules for cell killing. It also promotes a more activated phenotype (higher HLA-DR and CD69 expression).
- Improved Assay Sensitivity and Specificity: The combination of IL-15 treatment, optimized plasma dilution series, and baseline subtraction significantly improved the ability to detect ADCC responses and differentiate between vaccine and placebo groups.
- Implications for Vaccine Correlates: This optimized assay has direct implications for future HIV vaccine trials, enabling more accurate assessment of ADCC responses, which are hypothesized to be important correlates of protection.
Key Results
- Increased ADCC Activity: IL-15 pretreatment of effector cells led to a significant improvement in ADCC activity when tested with plasma from HIV-1 infected seropositive individuals and with well-characterized HIV-1 specific mAbs.
- Enhanced Response Rates in Vaccine Recipients: For vaccine recipients, the response rate for ADCC was substantially higher when IL-15-treated effector cells were used. Specifically, for IMC1086.c-infected cells, the rate increased from 38% to 85%, and for IMCCM235-infected cells, from 29% to 100%.
- Higher Magnitude of Responses: The peak baseline-subtracted ADCC responses were significantly higher in the presence of IL-15 for vaccine recipients across all tested HIV-1 IMCs, with median fold changes ranging from 1.39 to 3.6.
- Reduced Background Killing: IL-15 pretreatment also helped to reduce non-specific ADCC activity, particularly in negative control wells.
- NK Cell Phenotypic Changes: IL-15 treatment led to increased frequencies of CD56bright NK cells, decreased CD56dimCD16+ NK cells, and increased CD56dimCD16-/dim NK cells. It also increased intracellular perforin and granzyme B, and surface expression of HLA-DR and CD69.
Limitations and Future Work
- In Vitro vs. In Vivo Relevance: While IL-15 in vitro mimics in vivo activation, the exact concentration and mode of IL-15 presentation (e.g., trans-presentation) in the actual tissue microenvironment remain unknown. Further studies are needed to fully understand how in vitro findings translate to in vivo conditions.
- Background Reduction Mechanism: The study noted a reduction in background killing with IL-15 treatment but did not fully elucidate the mechanism behind this observation, suggesting it as an area for future investigation.
- Antigen-Related Variability: The magnitude of IL-15's enhancing effect and its ability to reduce variability showed some antigen-related differences, indicating that the specific HIV-1 Env target might influence the outcome.
- Future Directions: The authors suggest that these optimized analytical approaches, including IL-15 pretreatment and baseline subtraction, should be incorporated into future HIV vaccine clinical trial analyses to improve the detection and interpretation of ADCC responses. They also propose investigating the role of IL-15 in the context of mucosal immunity and its potential as an adjuvant in HIV vaccine strategies.
Summary updated